



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Koselugo

Page: 1 of 2

Effective Date: 8/7/2025

Last Review Date: 7/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Koselugo under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Compendial Uses²

- Circumscribed glioma, pleomorphic xanthoastrocytoma (PXA)
- Langerhans cell histiocytosis

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Koselugo

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review: Documentation of BRAF mutation status, where applicable.

Coverage Criteria

Neurofibromatosis type 1¹

Authorization of 12 months may be granted for treatment of neurofibromatosis type 1 (NF1) when the member has symptomatic, inoperable plexiform neurofibromas (PN).

Circumscribed Glioma, Pleomorphic Xanthoastrocytoma (PXA)²

Authorization of 12 months may be granted as a single agent for treatment of recurrent or progressive disease when any of the following criteria are met:

- Member has a circumscribed glioma and either of the following are met:



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Koselugo

Page: 2 of 2

Effective Date: 8/7/2025

Last Review Date: 7/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

- BRAF fusion or BRAF V600E activating mutation positive disease or
- Disease is WHO grade 1
- Member has a NF-1 mutated glioma
- Member has WHO grade 2 pleomorphic xanthoastrocytoma (PXA)

Langerhans Cell Histiocytosis²

Authorization of 12 months may be granted as a single agent for treatment of Langerhans cell histiocytosis.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit:

- Koselugo (selumetinib) 10 mg capsules: 240 capsules per 30 days
- Koselugo (selumetinib) 25 mg capsules: 120 capsules per 30 days

References:

1. Koselugo [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2024.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed February 26, 2025.